Data Insights

PRO-1107 by ProfoundBio Suzhou for Peritoneal Cancer: Likelihood of Approval

PRO-1107 is under clinical development by ProfoundBio Suzhou and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - PRO-1107 in Peritoneal Cancer

Data Insights

PRO-1107 by ProfoundBio Suzhou for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

PRO-1107 is under clinical development by ProfoundBio Suzhou and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to...

Likelihood of Approval and Phase Transition Success Rate Model - PRO-1107 in Triple-Negative Breast Cancer (TNBC)

Data Insights

PRO-1107 by ProfoundBio Suzhou for Esophageal Squamous Cell Carcinoma (ESCC): Likelihood of Approval

PRO-1107 is under clinical development by ProfoundBio Suzhou and currently in Phase II for Esophageal Squamous Cell Carcinoma (ESCC). According...

Likelihood of Approval and Phase Transition Success Rate Model - PRO-1107 in Esophageal Squamous Cell Carcinoma (ESCC)

Data Insights

PRO-1107 by ProfoundBio Suzhou for Epithelial Ovarian Cancer: Likelihood of Approval

PRO-1107 is under clinical development by ProfoundBio Suzhou and currently in Phase II for Epithelial Ovarian Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - PRO-1107 in Epithelial Ovarian Cancer

Data Insights

PRO-1107 by ProfoundBio Suzhou for Ureter Cancer: Likelihood of Approval

PRO-1107 is under clinical development by ProfoundBio Suzhou and currently in Phase II for Ureter Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - PRO-1107 in Ureter Cancer

Data Insights

PRO-1107 by ProfoundBio Suzhou for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval

PRO-1107 is under clinical development by ProfoundBio Suzhou and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction. According...

Likelihood of Approval and Phase Transition Success Rate Model - PRO-1107 in Adenocarcinoma Of The Gastroesophageal Junction

Data Insights

PRO-1107 by ProfoundBio Suzhou for Transitional Cell Cancer (Urothelial Cell Cancer): Likelihood of Approval

PRO-1107 is under clinical development by ProfoundBio Suzhou and currently in Phase II for Transitional Cell Cancer (Urothelial Cell Cancer)....

Likelihood of Approval and Phase Transition Success Rate Model - PRO-1107 in Transitional Cell Cancer (Urothelial Cell Cancer)

Data Insights

PRO-1107 by ProfoundBio Suzhou for Fallopian Tube Cancer: Likelihood of Approval

PRO-1107 is under clinical development by ProfoundBio Suzhou and currently in Phase II for Fallopian Tube Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - PRO-1107 in Fallopian Tube Cancer

Data Insights

PRO-1107 by ProfoundBio Suzhou for Non-Small Cell Lung Cancer: Likelihood of Approval

PRO-1107 is under clinical development by ProfoundBio Suzhou and currently in Phase II for Non-Small Cell Lung Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - PRO-1107 in Non-Small Cell Lung Cancer

Data Insights

PRO-1107 by ProfoundBio Suzhou for Endometrial Cancer: Likelihood of Approval

PRO-1107 is under clinical development by ProfoundBio Suzhou and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - PRO-1107 in Endometrial Cancer

Data Insights

PRO-1107 by ProfoundBio Suzhou for Solid Tumor: Likelihood of Approval

PRO-1107 is under clinical development by ProfoundBio Suzhou and currently in Phase II for Solid Tumor. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - PRO-1107 in Solid Tumor

Data Insights

PRO-1107 by ProfoundBio Suzhou for Bladder Cancer: Likelihood of Approval

PRO-1107 is under clinical development by ProfoundBio Suzhou and currently in Phase II for Bladder Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - PRO-1107 in Bladder Cancer

Data Insights

PRO-1107 by ProfoundBio Suzhou for Gastric Cancer: Likelihood of Approval

PRO-1107 is under clinical development by ProfoundBio Suzhou and currently in Phase II for Gastric Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - PRO-1107 in Gastric Cancer